Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07076771

Serum Testosterone Level on Angiographic Complexity of Coronary Lesions in Premature Ischemic Egyptian Males

This study aims to investigate the association between serum testosterone levels and the angiographic complexity of coronary artery lesions in male patients under 45 years of age presenting with premature ischemic heart disease.

Recruiting

Interested in participating?

Request Info

Key information

Age range

Up to 45 year

Sex eligibility

Male

Study type

Observational

Primary location

Sohag University

Sohag, 82511, Egypt

Location status: Recruiting

Location contact

Ahmed I Bedier, MD

PRINCIPAL_INVESTIGATOR

Remon S Adly, MD

CONTACT

[email protected]

00201221878986

Sherein F Aziz, MD

PRINCIPAL_INVESTIGATOR

About this study

Coronary artery disease (CAD) remains a leading cause of morbidity and mortality worldwide. While traditionally associated with older populations, there is a growing incidence of premature CAD.

Testosterone, the primary male sex hormone, exerts various physiological effects beyond its role in reproductive function. It influences muscle mass, fat distribution, insulin sensitivity, and vascular tone. Low testosterone levels have been associated with adverse metabolic profiles, including increased adiposity, dyslipidemia, and insulin resistance, all of which are established risk factors for atherosclerosis. Furthermore, testosterone deficiency has been linked to endothelial dysfunction, a critical early event in the development of atherosclerotic plaques.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male patients aged <45 years.
  • Diagnosed with premature ischemic heart disease.
  • Undergoing elective coronary angiography for suspected coronary artery disease (CAD) .

Exclusion criteria

  • History of acute coronary syndrome within the preceding 3 months.
  • Prior diagnosis of hypogonadism or history of testosterone replacement therapy or anabolic steroid use.
  • Active neoplasm or history of chemotherapy.
  • Known hepatic cirrhosis, chronic kidney disease, or end-stage renal disease.
  • Use of medications known to affect sex hormone levels (e.g., spironolactone, ketoconazole).
  • Endocrine disorders such as sickle cell anemia or celiac disease.

Treatment and study plan

Coronary Angiography

Other

All angiographic procedures will be performed. Coronary artery disease will be defined as >70% stenosis in at least one major epicardial artery or >50% the left main coronary artery.

SYNTAX Score

Other

The angiographic complexity of coronary artery disease (CAD) will be assessed using the SYNTAX score.

Primary outcomes

  1. Serum testosterone level

    Time frame: Immediately after angiography (Up to 1 hour)

    Serum testosterone level will be measured.

Study contacts

Contact information is provided by the study sponsor or research team.

Remon S Adly, MD

CONTACT

[email protected]

00201221878986

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Official study title

Impact of Serum Testosterone Level on Angiographic Complexity of Coronary Lesions in Premature Ischemic Egyptian Males

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jul 22, 2025
Registry last updated
Jul 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.